Work

Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.3505

Authors: Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, Richard Curry, Trisha Michel Wise-Draper, Vinay K. Puduvalli

Institutions: Augusta University, University of Cincinnati, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Montefiore Medical Center, Bexion Pharmaceuticals (United States), The Ohio State University Wexner Medical Center, The Ohio State University

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029360312

Cites:

Cited by: 1

Related to: 10